Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Trovagene

TrovaGene announced that it had achieved a positive finding using its drug onvansertib in combination with AbbVie's Venclexta in relapsed or refractory AML patients.

TrovaGene Proves Drug Success In Treating AML With Multiple Combinations

Biogen

Bristol-Myers

Celgene

Gilead Sciences

5 extremely cheap healthcare names with possible 30-50% upside potential.

5 Stocks To Own As Healthcare Bottoms

AbbVie Inc. shares ticked higher after the drug maker said Tuesday the Food and Drug Administration approved its psoriasis treatment Skyrizi.

AbbVie stock ticks higher on FDA approval of psoriasis treatment

AbbVie Inc. has been a poor performer over the past few years.

Trapping AbbVie

These two drug stocks have been the industry's biggest losers this year. Which is the better buy now?

Better Buy: Biogen vs. AbbVie

Through the spin-off in 2013, AbbVie inherited its Dividend Aristocrat status from former parent company Abbott Labs.

AbbVie: This Dividend Aristocrat Is Set To Crush The Market

Can the big drugmaker meet Wall Street's expectations this time around?

AbbVie Reports Its Q1 Results on Thursday: Here's What You Can Expect

Exelixis

Geron

These three cancer stocks have tremendous upside potential.

3 Cancer Treatment Stocks to Buy in April

Intercept Pharma

Pfizer

Vertex Pharmaceuticals

Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.

5 Top Pharmaceutical Stocks to Buy in 2019

Ligand Pharmaceuticals

Looking for potential winning biotech stocks? These five check off all the boxes for investors.

5 Top Biotech Stocks to Buy in 2019

There's nothing complicated at all about this approach to making a solid profit with one of the top big pharma stocks on the market.

The Simple Way You Could Make 10% Each Year With AbbVie

AbbVie obtained Japanese approval of SKYRIZI to treat patients with psoriasis.

AbbVie's Psoriasis Drug Approved For Japan, But The Main Event Is Yet To Come

A. O. Smith

Cardinal Health

Colgate-Palmolive

Federal Realty Investment Trust

General Dynamics

Hormel Foods

Coca-Cola

Walgreens

Dividend aristocrats and kings have proven themselves a great way to enjoy safe and growing dividends, even in recession, plus market-beating returns over time.

Bunker Dividend Growth Portfolio: Our Newest Dividend Aristocrat

Johnson & Johnson

Which of these healthcare titans is the better investment today? The answer might surprise you.

Better Buy: Johnson & Johnson vs AbbVie

Archer-Daniels-Midland Company

Polaris

SEI Investments

To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years.

Dividend Growth Stocks

Looking for big dividend payers? Here is a diversified trio of stocks that you need to take a look at today -- before their high yields are a thing of the past.

3 High-Yield Stocks at Rock-Bottom Prices: Abbvie

AstraZeneca

Bayer AG

Eli Lilly

Novartis

AstraZeneca announces a $6.9 billion cancer deal with Daiichi Sankyo. AbbVie (ABBV), Novartis (NVS) & AstraZeneca's (AZN) drugs get regulatory approvals.

Pharma Stock Roundup: AZN Inks Cancer Deal, ABBV, NVS & Others Get Drug Approvals

AbbVie (ABBV) closed the most recent trading day at $79.64, moving -0.15% from the previous trading session.

AbbVie Dips More Than Broader Markets

These four experimental drugs will reach the market soon, and the companies launching them have little room for error.

4 Blockbuster Drug Launches to Watch in 2019: AbbVie

DaVita

These stocks are dirt cheap. But perhaps not for too much longer.

Bargain Stocks You Can Buy Today

Where Will AbbVie Be in 10 Years?

AbbVie is one of the world's most interesting manufacturer's of medicine due to its history and future prospects.

AbbVie: Not A Swan, But A Steal At Its Current Price

It looks as if AbbVie's glorious days are over. The stock is down almost 30% from its 52-week high and down more than a third from its all-time high set in January 2018.

What Investors Are Missing About AbbVie

AbbVie Inc. and patients suffering from multiple myeloma have seen some additional bad news.

Bad News for AbbVie and Multiple Myeloma Patients

Shares of AbbVie Inc. fell 0.8% in premarket trade Tuesday.

News for AbbVie Stock (ABBV)